Corticosteroid Drugs: - Darmawan, dr.,M.Kes
Corticosteroid Drugs: - Darmawan, dr.,M.Kes
Corticosteroid Drugs: - Darmawan, dr.,M.Kes
• Darmawan,dr.,M.Kes
Introduction
Inflammation?
Trauma, microba, Ag, cold
cell
+ - (stricture, fibrosis)
Adrenal cortex
Glucocorticoids ~ CS (CORTISOL)
* antiinflammatory – immunosuppressive
* metabolic potency
Mineralocorticoids (Aldosteron)
* Sod water retention edema
BP
androgen
INTRODUCTION
1. Cs hormone
S.E . . . . . . . (1)
2. Therapeutic uses
* endocrine substitution th/.
* non endocrine
AI & IMMUNOSUPPRESIVE
regulation FBM
CS level FBM (+)
CS level FBM (-)
What happens to the patient who
chronically consume CS exogen in large
dosage ?
CS level FBH (-)
ATROPHY
DIURNAL CYCLE
Concentration in plasma
8 am : 16 mg/100 ml
4 pm : 4 mg/100 ml
Potency :
* antiinflammation : 1
* Na+ retention :1
* metabolic : 20
PHARMACOKINETICS
A : CS is a lipophylic drug
* Good : intestinal (p.o)
Conjunctival space (topical)
Synovial (p.e)
Nasal (spray)
* Slowly : skin
Good penetration : mucosa,
conjunctiva, scrotum - face
D : 80 – 90% is bound to globulin
5 – 10% albumin
The free fraction is 3 – 10%
CS is widely distribution
M : liver
: Rifampicin
Phenobarbital CS Met
Phenytoin
E : Kidney
MECHANISM OF ACTION
1. AFFECTS THE RNA TRANSCRIPTION RNA
2. INHIBITION OF PHOSPHOLIPID ENZYM
moon face
buffalo hump
supraclav deposit
atrophy
II. ANTIIMFLAMMATORY AND
IMMUNOSUPRESION
1. On vascular events
Reduced vasodilatation
Decreased fluid exudation
2. On cellular events
Indication
* in area of acute inflammation :
decreased ( ) number and activity of leucosit
* in area of chronic inflammation :
decreased activity of mononuclear cells.
Decreased fibroblast function
* in lymphoid areas :
decreased clonal expansion of T and B cells.
decreased action of cytokine – secreting T cells.
3. On inflammatory and immune mediators
decreased : cytokines (IL)
eicosanoid
PAF
complement
histamin
IV. CNS
euphoria withdrawl effect
treatment depression, sleep
disturbances, psychotic
V. STOMATCH
gastric acid
protective (mucopolysaccharidas)
VIII. EYE
Long term therapy intraocular pressure
glaucoma
blind ?
IX. GROWTH
X. REPRODUCTIVE
synthesis & secretion of gonadotropins
♂ : hypogonadism
♀ : anovulation, oligomenorrhea, uterine
bleeding
ADVERSE EFFECT
I. LARGE DOSE – LONG TERM CS
THERAPI
II. REBOUND PHENOMENE (WITH DRAWL
EFFECT)
>= 7 days
Abrupt stopped
Reactivation (exacerbation) of the disease
Anorexia, nausea, vomiting, weigh loss,
lethargy, headache, fever, joint-muscle
pain, postural hipotension
Tapering off or alternate day
INDICATION
1. Allergic drug reaction
2. Allergic rhinitis
3. Atopic dermatitis, exzema
4. Rheumatoid arthritis
5. Bronchial asthma
6. LLA
7. Organ transplants
8. Cerebral edem
9. Septicemia
10. Nephrotic syndrome
11. Lupus erythematic
CS SYNTHESIS
Compound Anti Na+ retaining Metabolic DOA Equivalent
Inflammatory Pot Pot Dose
Potency
Cortisol 1 1 20 S 20
Cortone 0,8 0,8 S
Prednisone 4 0,8 5 I 5
Prednisolone 4 0,8 5 I 5
Methylprednisolone 5 minimal I 4
Triamcinolone 5 0 4 I 4
Betamethasone 25 0 1 L 0,75
Dexamethasone 25 0 1-1,5 L 0,6
S : 8-12 h I : 12-36 h L : 36-72 h
DEXAMETHASONE
Synthetic CS
AI :
Na – water retaining potency :
Metabolic potency :
DOA : 36-72 h :
Indication : * patient with HT, DM
* acute therapy (septic shock-
brain edema)
SELECTION OF DRUG
1. REPLACEMENT THERAPY
3. THERAPY ACUTELY
P drugs Efficacy Safety Suitability Cost Notes
(%) (%) (%) (%)
Cortisol
Prednisone
Metilprednisolone
Dexamethasone
Triamcinolone
TOPICAL CORTICOSTEROID
Classification